de Bruyn G, Garner P
Department of Medicine, Baylor College of Medicine, Fondren-Brown Building, 6565 Fannin St, Houston, TX 77030, USA.
Cochrane Database Syst Rev. 2000;2003(2):CD001166. doi: 10.1002/14651858.CD001166.
Mycobacterium vaccae has been advocated for immunotherapy in the treatment of tuberculosis and other infections caused by mycobacteria.
The objective of this review was to assess the effects of Mycobacterium vaccae for treating tuberculosis.
We searched the Cochrane Infectious Diseases Group trials register, the Cochrane Controlled Trials register, Medline, Embase and reference lists of articles. We also contacted organisations and individuals working in the field.
Randomised and quasi-randomised trials of preparations of whole, killed Mycobacterium vaccae in patients with tuberculosis.
One reviewer assessed trial quality and extracted data.
Four trials met the inclusion criteria. There was no effect on mortality (2 trials, RR 1.01, 95% CI 0.50 to 2.04); no consistent effect on sputum negativity or sputum culture; and a high level of adverse reactions.
REVIEWER'S CONCLUSIONS: Immunotherapy with Mycobacterium vaccae does not appear to benefit patients with tuberculosis.
母牛分枝杆菌已被提倡用于结核病及其他分枝杆菌引起的感染的免疫治疗。
本综述的目的是评估母牛分枝杆菌治疗结核病的效果。
我们检索了Cochrane传染病组试验注册库、Cochrane对照试验注册库、医学期刊数据库、荷兰医学文摘数据库以及文章的参考文献列表。我们还联系了该领域的组织和个人。
关于全菌灭活母牛分枝杆菌制剂治疗结核病患者的随机和半随机试验。
由一名综述作者评估试验质量并提取数据。
四项试验符合纳入标准。对死亡率无影响（2项试验，相对危险度1.01，95%可信区间0.50至2.04）；对痰菌阴性或痰培养无一致影响；且不良反应发生率高。
母牛分枝杆菌免疫治疗似乎对结核病患者无益处。
